An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain; Pain
- Focus Adverse reactions
- Sponsors Mallinckrodt Inc.
- 02 Jun 2017 Planned End Date changed from 1 Oct 2016 to 1 Jan 2019.
- 02 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2019.
- 25 Dec 2014 New trial record